Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –– Verekitug ...

GSK PLC announced Japan?s Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix (GSK?s Recombinant Zoster Vaccine or RZV) for the prevention of ...

AstraZeneca announces tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON & TITANIA phase III trials: Cam ...

After Vaibhav, a Class 5 student in Kochi, developed a high fever and persistent dry cough, his parents initially treated it ...

AstraZeneca announced that full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly ...

The Biologics License Application for tozorakimab 300mg, administered once every four weeks, has been accepted for Priority Review by the US Food and Drug Administration as an add-on maintenance ...

About the RENEW Phase 2 Trial Rein’s RENEW trial (ClinicalTrials.gov: NCT06968845) is a randomized, placebo-controlled Phase 2 clinical study designed to evaluate the safety, tolerability, and ...

Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically ...

Patients describe it in different ways. Some say their vision turns fuzzy during a stressful week at work. Others notice a ...

Verekitug significantly reduced asthma exacerbations and improved lung function in Phase 2 trials; Phase 3 trials expected in ...

Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – ...

AstraZeneca said on 8 September 2026 that the US Food and Drug Administration has accepted for Priority Review its Biologics ...